VP-Business Development Max Mendelsohn is a full-time employee of the contract clinical laboratory and not employed as a consultant to his former company, Barre National. Clarifying a statement in the Sept. 16 issue of "The Pink Sheet" ("In Brief") about his relationship with his former firm, Mendelsohn said he has agreed that through 1992 he will counsel Barre as needed in matters requiring institutional memory. Before joining PharmaKinetics, Mendelsohn worked at Barre for 30 years. . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth